Tenecteplase thus officially joins the other stroke thrombolytic approved stateside, alteplase (Activase), which is also ...

Not to B-negative, but your blood type could offer a clue to your risk of having a stroke before 60. “The number of people with early strokes is rising,” said Dr. Steven J. Kittner ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

The Salt Substitute and Stroke Study, an open-label, randomized clinical trial, was conducted in 600 northern Chinese villages. The trial, which involved 20,995 participants, previously reported ...

Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

Tenecteplase thus officially joins the other stroke thrombolytic approved stateside, alteplase (Activase), which is also marketed by Genentech. Notably, off-label tenecteplase had already become ...